Elevated sleep-time blood pressure (BP) is a better predictor of cardiovascular risk than the awake or 24 h BP means. however, discrepancies in the diagnosis of hypertension between clinic and ambulatory measurements (isolated-office and masked hypertension) are frequently defined by comparing clinic with only awake BP. We evaluated the impact of sleep-time BP in the prognostic value of isolated-office and masked hypertension.
Blood pressure (BP) measured in the physician's office has long been used to diagnose hypertension and evaluate treatment efficacy. 1, 2 However, the correlation between BP level and target organ damage, cardiovascular disease (CVD) risk, and long-term prognosis is greater for ambulatory BP monitoring (ABPM) than clinical BP measurements. 3, 4 Current guidelines 1,2 define normotension and "sustained" hypertension as a consistently normal or elevated BP, respectively, on both clinic and ambulatory measurements. Discrepancies between the two measurements have been defined as isolated-office hypertension (elevated clinic BP but normal ambulatory BP), and masked hypertension (normal clinic BP but elevated ambulatory BP). 2 The same guidelines recommend the use of separate threshold values for daytime and nighttime BP means for diagnosis of hypertension based on ABPM. 1, 2 However, classification of subjects into isolated-office and masked hypertension has most frequently relied, as suggested in the guidelines themselves, 2 on comparison of clinic and awake BP mean, [5] [6] [7] [8] [9] [10] [11] disregarding entirely the asleep BP mean otherwise used to define hypertension.
Past studies have mostly, but not consistently, 5, 7, 12 suggested that CVD risk does not differ significantly between isolatedoffice hypertension and normotension, but is significantly higher in masked and sustained hypertension than in normotension. 6, [8] [9] [10] [11] A major limitation of all these previous studies is that, by classifying subjects from comparison of clinic and ambulatory awake or even 24 h BP measurements, 12 each of the four resulting categories could include individuals with normal and elevated asleep BP, and thus at a markedly different CVD risk. This appears to be clinically relevant because a growing number of studies have concluded that the nighttime BP mean is a better predictor of CVD risk than the awake or 24 h BP means. [13] [14] [15] [16] [17] [18] The Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares (MAPEC), (i.e., Ambulatory BP Monitoring for Prediction of Cardiovascular Events) study was specifically designed to investigate prospectively whether specific changes original contributions
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in the circadian BP profile during follow-up results in reduced CVD risk. [18] [19] [20] [21] The data of this study makes possible prospective examination of the impact of sleep-time BP in the definition of ambulatory hypertension and the associated prognostic value of isolated-office and masked hypertension, conditions of disagreement in the diagnosis of hypertension, i.e., high CVD risk, between clinic and ambulatory BP measurements.
Methods
Inclusion and exclusion criteria. An extended version of the Methods is available in the Supplementary Methods online. In summary, the sample represents a population of Spanish subjects, ≥18 years of age. Inclusion criteria required subjects be either normotensive, untreated hypertensive, or resistant to treatment (uncontrolled BP according to the ABPM threshold values outlined below while compliant to three optimally dosed hypertension medications of different classes, or any patient treated with ≥4 hypertension medications), when ingesting all their prescribed BP-lowering medications upon awakening. Exclusion criteria were pregnancy, history of drug/ alcohol abuse, night/shift-work employment, diagnosis of AIDS, type 1 diabetes, secondary hypertension, CVD disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure, and grade III-IV retinopathy), intolerance to ABPM, and inability to communicate and comply with all of the study requirements. This prospective single-center study (registered at www.clinicaltrials. gov, with identifier code NCT00295542) was approved by the state Ethics Committee of Clinical Research. All participants gave written informed consent.
Subjects and diagnostic criteria. Between 2000 and 2007 we recruited 3,612 subjects fulfilling the inclusion/exclusion criteria. Among these, 3,344 (1,718 men/1,626 women, 52.6 ± 14.5 (mean ± s.d.) years of age) provided all required information for the study. The remaining 268 subjects were disqualified due to inadequate ABPM sampling at baseline and lack of consent for additional ABPM evaluations. Diagnosis of hypertension in untreated subjects was based on accepted ABPM criteria, i.e., an awake systolic BP (SBP)/diastolic BP (DBP) mean ≥135/85 mm Hg and/or an asleep SBP/DBP mean ≥120/70 mm Hg. 2 The corresponding thresholds for conventional clinic BP, used only for comparative purposes, were 140/90 mm Hg for SBP/DBP. 2 Study design. Complete details of the rationale and design of the MAPEC study are described elsewhere. 19, 20 A major goal of the study was to assess the effect of the treatment-time of prescribed BP-lowering medications on CVD risk. Thus, hypertensive patients were randomized to either ingest all BP-lowering medications upon awakening, or ≥1 of them at bedtime. Results on the influence of treatment-time on CVD risk have been previously reported. 20, 21 Blood samples were obtained between 08:00 and 09:00 h, after overnight fasting, the same week when each 48 h ABPM session was initiated. Just before commencing each 48 h ABPM session, the same investigator obtained six consecutive clinic BP measurements using a validated automatic oscillometric device (HEM-705IT; Omron Health Care, Vernon Hills, IL) after the subject had rested in a seated position for ≥10 min.
ABPM assessment. At inclusion, as well as at each scheduled visit for ABPM during follow-up (see below), the SBP and DBP of each subject were automatically measured every 20 min between 07:00 and 23:00 h and every 30 min during the night for 48 consecutive hours with a calibrated SpaceLabs 90207 ABPM monitor (SpaceLabs, Issaquah, WA). BP series were considered invalid for analysis if ≥30% of the measurements were missing, if data were lacking for an interval of >2 h, or if the nighttime sleep period was <6 h or >12 h during ABPM. If invalid according to these criteria, participants were requested to repeat ABPM within the same week.
Actigraphy. All participants wore an actigraph (Mini-MotionLogger; Ambulatory Monitoring, Ardsley, NY) on the dominant wrist to quantify physical activity at 1-min intervals during 48 h ABPM. The actigraphy data, combined with patient diaries, were used to corroborate the absence of daytime napping and to define the commencement and termination of the daytime awake and nighttime asleep spans, so the respective SBP and DBP means of each participant could be accurately determined.
Follow-up. The same evaluation procedure described above, including clinic BP measurement, 48 h ABPM, and wrist activity monitoring, was scheduled annually for all participants, or more frequently (3 months after any change in therapy in treated patients) if the therapeutic scheme was modified to improve ambulatory BP control. Investigators blinded to the timed-treatment scheme of the randomized participants (excluding those performing clinic evaluation at each visit to the hospital, clinic and ambulatory BP measurement, and/or statistical analyses) reviewed at least annually, as well as for a year after the last ABPM evaluation was performed, the complete clinical records of all enrolled patients to assess CVD morbidity and mortality. Registered events included: death from all causes, myocardial infarction, angina pectoris, coronary revascularization, heart failure, acute arterial occlusion of the lower extremities, thrombotic occlusion of the retinal artery, hemorrhagic stroke, ischemic stroke, and transient ischemic attack.
Statistical methods. The primary study endpoint was total CVD morbidity and mortality, which included all the events listed in the previous section. We additionally analyzed major CVD events, i.e., a composite of CVD deaths, myocardial infarction, ischemic stroke, and hemorrhagic stroke. Subjects were divided into four investigated categories (normal BP, isolated-office hypertension, masked hypertension, and sustained hypertension) according to the agreement/disagreement between the diagnosis of hypertension based on clinic and ambulatory BP measurements. We compared CVD risk original contributions Table 1 provides comparative information between the four investigated categories obtained by comparing the diagnosis of hypertension based on clinic BP and that derived from both awake and asleep BP thresholds (outlined before) used jointly, according to the current definition of hypertension/normotension based on ABPM. 2 All data represent the last available ABPM evaluation of each subject. We believe this evaluation to be clinically more relevant than the baseline or any other evaluation during follow-up; according to the protocol described above, this last evaluation provides information on the clinic and ambulatory BP obtained for each participant within 1 year previous to either having or not having a CVD event. Diabetes, metabolic syndrome, and obesity, were more frequent among subjects with isolated-office and sustained hypertension (P < 0.001), while obstructive sleep apnea and chronic kidney disease were more frequent in masked and sustained hypertension (P < 0.001). Ambulatory SBP was progressively higher across the four categories defined in Table 1 . Ambulatory DBP was comparable between subjects with normal BP and isolated-office hypertension, and higher in the other two categories (P < 0.001). The sleep-time relative BP decline was significantly greater in subjects with normal BP and isolated-office hypertension than in the other two groups. Accordingly, the prevalence of nondipping was larger in subjects with either masked or sustained hypertension (P < 0.001).
cVd risk of isolated-office and masked hypertension defined according to awake BP, asleep BP, or both
We first divided the subjects into the four categories resulting from comparing clinic BP with awake BP mean, as customary in most previous published studies on this topic. Figure 1a shows a nonsignificant tendency of increasing adjusted HR of total CVD events across the four categories. Adjustments were applied for sex, age, diabetes, chronic kidney disease, sleep duration, and treatment-time, as these influential factors were the only ones, among the variables shown in Table 1 , that were consistently significant in most tested Cox regression models. Other potentially relevant variables among those included in Table 1 were not significant predictors of outcome in the Cox models after including these confounding variables. Adjusted HR was comparable between subjects with normal BP, isolated-office, and masked hypertension. Subjects with sustained hypertension had higher HR than those with normal BP (P < 0.001), but comparable HR as those with masked hypertension (P = 0.55; Figure 1a ). Results and conclusions were similar when analyses were restricted to major CVD events (Figure 1b) , although there was, however, a borderline significant difference (P = 0.044) in adjusted HR of major CVD events between normal BP and masked hypertension, but not between normal BP and isolated-office hypertension (P = 0.47) nor between isolated-office hypertension and masked hypertension (P = 0.11; Figure 1b) .
We also used the 48 h BP mean, in comparison with clinic BP, for classification and comparison of office and out-of-office hypertension (Figure 2a for total events and Figure 2b for major events). ABPM-derived 48 h BP mean was considered normal if <125/80 mm Hg and elevated otherwise. 2 Results (Figure 2) , mainly identical to those derived from awake BP mean, indicate increased HR of CVD events only in sustained hypertension.
Subjects were further divided into four categories resulting from comparing clinic BP with asleep BP mean. Results indicate: (i) comparable adjusted HR of total (P = 0.48; Figure 3a ) and major CVD events (P = 0.54; Figure 3b ) between normal BP and isolated-office hypertension; (ii) nonsignificantly different adjusted HR between masked and sustained hypertension (P < 0.37); and (ii) highly significant greater HR in masked and sustained hypertension compared to either normal BP or isolated-office hypertension (P < 0.001).
We finally divided the subjects into four categories by comparing clinic BP with both ABPM-derived awake and asleep BP means, as a joint unique criterion for defining hypertension vs. normotension. The comparison of adjusted HR between the four categories is illustrated in Figure 4 . Results, showing significantly higher HR in masked and sustained hypertension compared to normal BP and isolated-office hypertension, are similar to those described in Figure 3 for subjects classified according to asleep BP mean alone.
influence of asleep BP on cVd risk in subjects divided according to clinic and awake BP We evaluated the risk of CVD events in the eight resulting categories of classifying subjects according to clinic, awake, and asleep BP as three different diagnostic variables ( Table 2) . Adjusted HR of each group was calculated by comparison with the reference subjects with normal clinic, awake, and asleep BP (group 1). The results can be summarized as follows (95% confidence intervals for all HRs are provided in Chronic kidney disease: estimated glomerular filtration rate <60 ml/min/1.73 m 2 , albuminuria, or both, in at least two occasions ≥3 months apart. 26 Total events include: death (from all causes), cardiovascular events (myocardial infarction, angina pectoris, and coronary revascularization), cerebrovascular events (stroke and transient ischemic attack), heart failure, and other events (acute arterial occlusion of lower extremities and thrombotic occlusion of the retinal artery). Major events include: cardiovascular deaths, myocardial infarction, ischemic stroke, and hemorrhagic stroke. The sleep-time relative BP decline, an index of BP dipping, is defined as the percent decline in BP during nocturnal rest relative to the mean BP obtained during daytime activity, and calculated as: ((awake BP mean-asleep BP mean)/awake BP mean) × 100. Nondipper: subjects with sleep-time relative SBP decline <10%, using data sampled by ABPM for 48 consecutive hours. For classification, clinic BP was considered normal if <140/90 mm Hg for SBP/DBP and elevated otherwise. Ambulatory BP was considered normal if the awake BP mean was <135/85 mm Hg for SBP)/ DBP and the asleep BP mean was <120/70 mm Hg, and elevated otherwise. Normal BP and sustained hypertension (HT) are here defined as consistently normal BP or elevated BP, respectively, on both clinic and ambulatory measurements; isolated-office HT is defined as elevated clinic BP but normal ABPM; and masked HT is defined as normal clinic BP but elevated ABPM. ABPM, ambulatory BP monitoring; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic BP; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic BP. a Glomerular filtration rate (ml/min/1.73 m 2 ) was estimated using the CKD-EPI equation. 27 b Values correspond to the average of 6 clinic BP measurements obtained for each subject at the clinic before starting 48 h ABPM.
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HR (1.68; P = 0.034) than subjects with normal BP in all three BP characteristics (group 1), but comparable to that of subjects with normal clinic BP with elevated awake and asleep BP (group 4; HR 1.77, P = 0.039 compared to group 1). 2. Subjects with normal asleep BP, elevated awake BP, and normal clinic BP (usually classified as masked hypertension; group 3) had comparable HR to the reference group of normotensive subjects (0.71; P = 0.63). 3. Subjects with elevated asleep BP, normal awake BP, and elevated clinic BP (usually classified as isolated-office hypertension; group 6) had significantly greater HR than the reference group of normotensive subjects (2.08; P < 0.001), but comparable to that of subjects with elevated BP in all three characteristics, group 8; 2.36; P < 0.001 compared to group 1). 4. Subjects with normal asleep BP, elevated awake BP, and elevated clinic BP (usually classified as sustained hypertension; group 7) had HR not significantly different than that of the reference group of normotensive subjects (0.61; P = 0.35), and fully comparable to that of subjects with elevated clinic BP but normal awake and asleep BP (group 5; 0.87; P = 0.50).
In order to further investigate the clinical impact of awake and asleep BP on CVD risk, we divided the studied population into four groups according to BP level, i.e., normal or elevated, using the thresholds provided above, independent of clinic BP. The results, as depicted in Figure 5 , indicate that: (i) adjusted HR was comparable in subjects with normal asleep BP, independent of the awake BP; (ii) HR was comparable between subjects with elevated asleep BP, independent of the awake BP; and (iii) subjects with elevated asleep BP had significantly higher HR than subjects with normal asleep BP, independent of the awake BP. The results are identical both for total CVD events (Figure 5a ) and major CVD events (Figure 5b) , as well as for untreated and treated patients analyzed separately (data not shown). Cox proportional-hazard analysis using both the awake and asleep BP means as potential predictors of CVD risk revealed that the asleep SBP mean was an independent 
discussion
The results from this study on the prognostic value of ABPM, using highly reproducible 48 h ABPM and wrist actigraphy, in a relatively large cohort of subjects with baseline BP ranging from normotension to hypertension, corroborate, first, the higher prognostic value of CVD events for ABPM than clinic BP measurements as documented in previous studies, 3, 4 mainly when asleep BP is used for classification and CVD risk assessment. Results, in agreement with most cross-sectional studies on this topic, [13] [14] [15] [16] [17] indicate that the asleep SBP mean best predicted CVD events in a Cox proportional-hazard model adjusted by relevant confounding variables. 18 Awake BP, however, was not a significant predictor of CVD outcome in a fully adjusted model also including asleep BP mean ( Figure 5) . Various potential mechanisms supporting elevated asleep BP as the best predictor of CVD morbidity and mortality have been extensively summarized before. 22 Results shown in Table 2 indicate that there might be only two possible groups of subjects when using BP measurements for CVD risk assessment: Those with either normal asleep BP (relative lower HR) or elevated asleep BP (significantly higher HR), independently of the level of either clinic or awake BP measurements. In keeping with the main objective of the present report, our findings document the limitations of conclusions, sometimes contradictory, derived from many previous studies pertaining to the prognostic value of isolated-office and masked hypertension. Such studies, following the published recommendation of international guidelines, 1,2 classified subjects into the classes of normotension, isolated-office hypertension, masked hypertension, and sustained hypertension by comparing clinic with awake BP mean. [5] [6] [7] [8] [9] [10] [11] While each of these two BP measurements, as virtually any parameter derived from conventional, home, or ambulatory BP, are to some extent individually correlated with CVD risk, none of them provide any valuable added prognostic information when the asleep BP is used as a confounding variable for survival analyses. 18 Using the arguable form of classification based on awake BP mean alone to define out-of-office hypertension (Figure 1) , each of the four resulting categories included subjects with either original contributions
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normal or elevated asleep BP and thus of markedly different CVD risk ( Table 2) . The use for classification of the 24 h BP mean, instead of awake BP, in a minority of reports 12 does not seem to be adequate either (Figure 2 ). First, current guidelines recommend the preferable use of awake and asleep BP means, instead of the 24 h mean, for diagnosis of hypertension; 1 second, subjects with exactly the same 24 h BP mean might have a BP pattern ranging from extreme-dipping to rising (asleep BP above awake BP mean), and would thus have markedly different CVD risk. [13] [14] [15] [16] Accordingly, while most previous studies included as isolated-office hypertension groups 5 and 6 among those described in Table 2 (adjusted HR 0.87 and 2.08, respectively, compared to the reference group 1 of normotension), the use of asleep BP as the proper classification criterion would identify isolated-office hypertension as groups 5 and 7 (HR 0.87 and 0.61, respectively). On the other hand, previous studies consistently labeled as masked hypertension groups 3 and 4 (HR 0.71 and 1.77), whereas the approach we recommend would identify this condition in groups 2 and 4 (HR 1.68 and 1.77).
Apart from the marked difference in CVD risk assessment when using awake or asleep BP means for comparison with clinic BP, our findings indicate the reported information on the prevalence of the resulting four categories, and thus on the real clinical dimension of isolated-office and masked hypertension, is surely incorrect. According to the results summarized in Table 2 , 58.2% of subjects who should be labeled as masked hypertension based on their elevated asleep BP (group 2) have been so far classified as normotensive (based on normal awake BP) and thus mistakenly included in the reference group for evaluating CVD risk of other categories; 38.2% of subjects with normal asleep BP and thus at low CVD risk (group 3) have been always classified as masked hypertension; 12.6% of subjects that should be considered as isolated-office hypertension (group 7) have been classified as sustained hypertension; and 26.3% of subjects with sustained hypertension (group 6) have been consistently classified as isolated-office hypertension. Table 2 also documents that the combined use of awake and asleep BP means for classification and risk stratification might also be somehow misleading (Figure 4) , as awake BP adds little, if any (Figure 5 ), original contributions
prognostic information to the diagnosis of hypertension based on asleep BP. 18 Our study has some potential limitations. Although the number of evaluated subjects was considerably greater to that of most studies on the prognostic value of isolated-office and masked hypertension, 9,11 our study provides limited information on the CVD risk of some categories with low prevalence among those described in Table 2 . Nonetheless, the design of our study also incorporated several strengths. While all previous trials on the prognostic value of ABPM relied on a single baseline profile from each subject, our study was the first to perform systematic periodic evaluations by ABPM throughout the median 5.6 years of follow-up. This so-far unique approach allowed for the first time determination of ambulatory BP within one year before each documented event.
Further strengths of our study are the use of: (i) 48 h, instead of the most common 24 h ABPM sampling, to increase the reproducibility of the BP findings; 23 and (ii) wrist actigraphy to precisely and individually determine the beginning and end of the activity and sleep spans for each subject to enable accurate calculation of the awake and asleep BP means.
International guidelines 1,2 have already recognized the prognostic value of ABPM, and suggest limited clinical situations in which the technique is recommended, whereas stating that clinic BP should still be used as the reference gold standard for diagnosis of hypertension. 2 Our findings challenge these recommendations and, taking into account the prognostic value of asleep BP, support ABPM as a requirement for proper CVD risk assessment. Indeed, the recent update of the guidelines for clinical management of primary hypertension in adults from the National Institute for Health and Clinical Excellence already proposes the need for ABPM as a requirement for corroborating the diagnosis of hypertension in all adults with elevated clinic BP. 24 Our results further indicate that classification of subjects into categories of normotension, isolated-office hypertension, masked hypertension, and sustained hypertension, as well as the diagnosis of out-of-office hypertension as such, cannot be based just on awake BP mean, as so far customary in most available literature. HR (adjusted by the significant confounding variables of sex, age, diabetes, time of hypertension treatment (all medications upon awakening vs. ≥1 at bedtime), duration on nighttime sleep and chronic kidney disease) was obtained by Cox regression analysis using as reference group the subjects with normal BP according to all three different BP measurements (clinic BP, awake BP, and asleep BP; group 1). Daytime clinic BP was considered normal if <140/90 mm Hg for SBP/DBP and elevated otherwise. ABPM-derived awake BP mean was considered normal if <135/85 mm Hg and elevated otherwise. ABPM-derived asleep BP mean was considered normal if <120/70 mm Hg and elevated otherwise. In each of the columns 4-6, normal BP and sustained hypertension (HT) are defined as consistently normal BP or elevated BP, respectively, on both clinic BP and the used ABPM parameter; isolated-office HT is defined as elevated clinic BP but normal ABPM; and masked HT is defined as normal clinic BP but elevated ABPM. Column 9 (event-rate) provides the percentage of subjects with a documented event in each of the resulting eight categories. ABPM, ambulatory BP monitoring; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic BP; HR, hazard ratio; SBP, systolic BP.
